Co-Authors
This is a "connection" page, showing publications co-authored by Jeffrey Borgia and Mary Jo Fidler.
Connection Strength
2.305
-
The serum-based VeriStrat? test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. 2018 03 20; 18(1):310.
Score: 0.658
-
Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy. Oncotarget. 2017 Aug 29; 8(35):58108-58121.
Score: 0.618
-
Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy. Cancers (Basel). 2021 Mar 20; 13(6).
Score: 0.202
-
Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition. J Immunol Methods. 2021 03; 490:112956.
Score: 0.200
-
Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients. Cancers (Basel). 2019 Oct 23; 11(11).
Score: 0.184
-
Prognostic Significance of Skeletal Muscle Loss During Early Postoperative Period in Elderly Patients with Esophageal Cancer. Ann Surg Oncol. 2019 Nov; 26(12):3807-3808.
Score: 0.182
-
Practical and theoretical implications of weight gain in advanced non-small cell lung cancer patients. Ann Transl Med. 2017 Mar; 5(6):152.
Score: 0.153
-
Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Ther Adv Med Oncol. 2012 Mar; 4(2):51-60.
Score: 0.108